Flonase

Phase 3Protein / enzyme

Teva

Flonase is one of 83 small molecule programs targeting Allergic Rhinitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic RhinitisActive, not recruiting

Chronic RhinosinusitisActive, not recruiting

Chronic Rhinosinusitis With Nasal PolypsActive, not recruiting

Allergic RhinitisPhase 3

Active, not recruiting

Chronic RhinosinusitisPreclinical

Active, not recruiting

Chronic Rhinosinusitis With Nasal PolypsPhase 2

Active, not recruiting

Competition

Competitive Landscape

271 competitors in Allergic Rhinitis

#DrugCompanyPhaseTrials

Kenalog

BBassett Healthcare

Phase 3

1 2

Flonase

Teva

Phase 3

1 3

Asmanex HFA

Sumitomo Pharma America, Inc.

Phase 3

1 4

Ciclesonide HFA

Sumitomo Pharma America, Inc.

Phase 3

3 5

EMS Acarbose

EEMS

Phase 3

2 6

Asmanex

Novartis

Preclinical

12 7

HL151

HHanlim Pharm. Co., Ltd.

Phase 3

1 8

Veramyst

GSK

Preclinical

10 9

Singulair

AstraZeneca

Preclinical

5 10

Xolair

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Allergic Rhinitis1 trial

Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients

Terminated· Teva logo

Teva·Phase 3·NCT02246920·1,474 enrolled

Chronic Rhinosinusitis1 trial

Perioperative Oral Steroids for Chronic Rhinosinusitis Without Polyps (CRSsNP)

Completed·SStanford University·N/A·NCT02748070·81 enrolled

Chronic Rhinosinusitis With Nasal Polyps1 trial

Doxycycline in Treating Patients With Chronic Rhinosinusitis With Nasal Polyps

Terminated·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT02569437·49 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Flonase. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Flonase compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Flonase. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Teva company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: Teva

Flonase

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Allergic Rhinitis1 trial

Chronic Rhinosinusitis1 trial

Chronic Rhinosinusitis With Nasal Polyps1 trial

References

Drug Info

Quick Facts

Related News